| Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability PJM Brouwer, TG Caniels, K van der Straten, JL Snitselaar, Y Aldon, ... Science 369 (6504), 643-650, 2020 | 1162 | 2020 |
| Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate S Bangaru, G Ozorowski, HL Turner, A Antanasijevic, D Huang, X Wang, ... Science 370 (6520), 1089-1094, 2020 | 319 | 2020 |
| Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity H Liu, NC Wu, M Yuan, S Bangaru, JL Torres, TG Caniels, ... Immunity 53 (6), 1272-1280. e5, 2020 | 205 | 2020 |
| A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface S Bangaru, S Lang, M Schotsaert, HA Vanderven, X Zhu, N Kose, ... Cell 177 (5), 1136-1152. e18, 2019 | 203 | 2019 |
| An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain NC Wu, M Yuan, H Liu, CCD Lee, X Zhu, S Bangaru, JL Torres, ... Cell reports 33 (3), 2020 | 153 | 2020 |
| Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern H Cho, KK Gonzales-Wartz, D Huang, M Yuan, M Peterson, J Liang, ... Science translational medicine 13 (616), eabj5413, 2021 | 82 | 2021 |
| A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA S Bangaru, H Zhang, IM Gilchuk, TG Voss, RP Irving, P Gilchuk, P Matta, ... Nature Communications 9 (1), 2669, 2018 | 73 | 2018 |
| A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody NC Wu, M Yuan, S Bangaru, D Huang, X Zhu, CCD Lee, HL Turner, ... PLoS pathogens 16 (12), e1009089, 2020 | 65 | 2020 |
| H7N9 influenza virus neutralizing antibodies that possess few somatic mutations NJ Thornburg, H Zhang, S Bangaru, G Sapparapu, N Kose, RM Lampley, ... The Journal of clinical investigation 126 (4), 1482-1494, 2016 | 65 | 2016 |
| Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses JMJ Tas, JH Koo, YC Lin, Z Xie, JM Steichen, AM Jackson, BM Hauser, ... Immunity 55 (10), 1856-1871. e6, 2022 | 64 | 2022 |
| Influenza H7N9 virus neuraminidase-specific human monoclonal antibodies inhibit viral egress and protect from lethal influenza infection in mice IM Gilchuk, S Bangaru, P Gilchuk, RP Irving, N Kose, RG Bombardi, ... Cell host & microbe 26 (6), 715-728. e8, 2019 | 54 | 2019 |
| Structural basis of protection against H7N9 influenza virus by human anti-N9 neuraminidase antibodies X Zhu, HL Turner, S Lang, R McBride, S Bangaru, IM Gilchuk, W Yu, ... Cell host & microbe 26 (6), 729-738. e4, 2019 | 53 | 2019 |
| A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection H Liu, M Yuan, D Huang, S Bangaru, F Zhao, CCD Lee, L Peng, ... Cell host & microbe 29 (5), 806-818. e6, 2021 | 51 | 2021 |
| Structure and immune recognition of the porcine epidemic diarrhea virus spike protein RN Kirchdoerfer, M Bhandari, O Martini, LM Sewall, S Bangaru, KJ Yoon, ... Structure 29 (4), 385-392. e5, 2021 | 46 | 2021 |
| Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains HL Turner, J Pallesen, S Lang, S Bangaru, S Urata, S Li, CA Cottrell, ... PLoS biology 17 (2), e3000139, 2019 | 37 | 2019 |
| Structural mapping of antibody landscapes to human betacoronavirus spike proteins S Bangaru, A Antanasijevic, N Kose, LM Sewall, AM Jackson, ... Science Advances 8 (18), eabn2911, 2022 | 26 | 2022 |
| Recognition of influenza H3N2 variant virus by human neutralizing antibodies S Bangaru, T Nieusma, N Kose, NJ Thornburg, JA Finn, BS Kaplan, ... JCI insight 1 (10), 2016 | 26 | 2016 |
| Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface SJ Zost, J Dong, IM Gilchuk, P Gilchuk, NJ Thornburg, S Bangaru, N Kose, ... The Journal of Clinical Investigation 131 (15), 2021 | 24 | 2021 |
| Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants H Cho, KK Gonzales-Wartz, D Huang, M Yuan, M Peterson, J Liang, ... bioRxiv, 2021 | 13 | 2021 |
| Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A (H3N2) variant vaccine in healthy persons≥ 18 years old WA Keitel, LA Jackson, S Edupuganti, PL Winokur, MJ Mulligan, ... The Journal of infectious diseases 212 (4), 552-561, 2015 | 11 | 2015 |
